MONTREAL, June 10, 2013 /CNW Telbec/ - As a proud sponsor for 18 years
now of the Bourse Fernand-Seguin, one of Canada's most prestigious
fellowships for scientific journalism, Merck would like to offer
heartfelt congratulations to this year's recipients.
Anabel Cossette Civitella was awarded the Bourse Fernand-Seguin by jury
members for her article entitled "Machine cherche cerveau" [Machine Seeking Brain]. Looking at the interaction between brain and
machine to develop thought-controlled devices, her article explains an
innovation that would circumvent paralysis. The 23-year-old author
majors in international development and minors in psychology. She will
be awarded a $12,000 bursary along with a six-month internship in
"The Bourse Fernand-Seguin is a major stepping stone for young science
communicators in Québec, who play an important role in disseminating
new discoveries and popularizing the scientific issues of today and
tomorrow," says Jennifer Chan, Vice President, Policy and
Communications at Merck Canada. "Merck is proud to be associated with
the emergence of these new talents in science writing."
"The Bourse Fernand-Seguin is a monument of scientific culture in
Québec, and Merck has been part of this long tradition through its
support for emerging talent in science journalism year after year,"
says Binh An Vu Van, President of the Association des communicateurs
scientifiques du Québec. "Its ongoing contribution has made the company
one of the pillars of the bursary. As a science journalist, I am also
pleased to see that Merck, a major player in the pharmaceutical
industry, understands the value of quality science journalism and has
spent years taking an interest in and supporting it, and pursuing a
dialogue with associations like ours."
Merck Canada is committed to supporting young people who share its
enthusiasm for research and scientific progress through various
projects, such as the Science Fairs, which it has been supporting for
more than 20 years, and the Bourse Fernand-Seguin. The company firmly
believes in its commitment to the community. Merck's contribution to
the Bourse Fernand-Seguin is a natural extension of its efforts to
raise public awareness about science.
Today's Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our medicines, vaccines, biologic therapies, and consumer and
animal products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate
our commitment to increasing access to healthcare through far-reaching
policies, programs and partnerships. For more information about our
operations in Canada, visit www.merck.ca.
This news release includes "forward-looking statements" within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. These statements are based
upon the current beliefs and expectations of Merck's management and are
subject to significant risks and uncertainties. There can be no
guarantees with respect to pipeline products that the products will
receive the necessary regulatory approvals or that they will prove to
be commercially successful. If underlying assumptions prove inaccurate
or risks or uncertainties materialize, actual results may differ
materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care
cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product
development, including obtaining regulatory approval; Merck's ability
to accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of
Merck's patents and other protections for innovative products; and the
exposure to litigation, including patent litigation, and/or regulatory
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can
be found in Merck's 2012 Annual Report on Form 10-K and the company's
other filings with the Securities and Exchange Commission (SEC)
available at the SEC's Internet site (www.sec.gov).
SOURCE: Merck Canada Inc.
For further information: